Zobrazeno 1 - 10
of 660
pro vyhledávání: '"enadenotucirev"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Daruka Mahadevan, Tom Lillie, Wael Harb, Jordan Berlin, Mark Powell, Marwan Fakih, Lee Rosen, David Krige, Minesh Patel, Hani Babiker, Jo Carter, Chris Cox, Lola Parfitt
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 4 (2023)
Background Novel combination therapies to overcome anti-PD-1 resistance are required. Enadenotucirev, a tumor-selective blood stable adenoviral vector, has demonstrated a manageable safety profile and ability to increase tumor immune-cell infiltratio
Externí odkaz:
https://doaj.org/article/de3a1435f76c4ebb907b9143fa4f7517
Autor:
Jean-Pascal Machiels, Ramon Salazar, Sylvie Rottey, Ignacio Duran, Luc Dirix, Karen Geboes, Christine Wilkinson-Blanc, Gillian Pover, Simon Alvis, Brian Champion, Kerry Fisher, Hilary McElwaine-Johnn, John Beadle, Emiliano Calvo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Abstract Background Enadenotucirev is a chimeric adenovirus with demonstrated preclinical tumor-selective cytotoxicity and a short half-life. Further clinical mechanism of action data showed that enadenotucirev can gain access to and replicate within
Externí odkaz:
https://doaj.org/article/26c0983875fa4d0da5e0fc2f0a11a2aa
Autor:
Taverner, William K., Jacobus, Egon J., Christianson, John, Champion, Brian, Paton, Adrienne W., Paton, James C., Su, Weiheng, Cawood, Ryan, Seymour, Len W., Lei-Rossmann, Janet
Publikováno v:
In Molecular Therapy - Oncolytics 20 December 2019 15:117-130
Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus
Autor:
Sam Illingworth, Ying Di, Maxine Bauzon, Janet Lei, Margaret R. Duffy, Simon Alvis, Brian Champion, André Lieber, Terry Hermiston, Len W. Seymour, John Beadle, Kerry Fisher
Publikováno v:
Molecular Therapy: Oncolytics, Vol 5, Iss C, Pp 62-74 (2017)
Enadenotucirev is an oncolytic group B adenovirus identified by a process of bio-selection for the ability to selectively propagate in and rapidly kill carcinoma cells. It is resistant to inactivation by human blood components, potentially enabling i
Externí odkaz:
https://doaj.org/article/a7c13d435d3b499f8c2068ee8f9375b9
Autor:
Hillson, Lily V., Johnson, Jethro, Ji, Rui Ru, Rosen, Oliver, Qiao, Yu, Ooms, Alex, Maughan, Timothy S., Roxburgh, Campbell S., Hawkins, Maria, O'Cathail, Sean M.
Publikováno v:
In Radiotherapy and Oncology May 2024 194 Supplement 1:S5228-S5230
Autor:
Séan M. O’Cathail, Steven Davis, Jane Holmes, Richard Brown, Kerry Fisher, Leonard Seymour, Richard Adams, James Good, David Sebag-Montefiore, Tim Maughan, Maria A. Hawkins
Publikováno v:
Radiation Oncology, Vol 15, Iss 1, Pp 1-8 (2020)
Abstract Background Chemoradiotherapy remains the standard of care for locally advanced rectal cancer. Efforts to intensify treatment and increase response rates have yet to yield practice changing results due to increased toxicity and/or absence of
Externí odkaz:
https://doaj.org/article/7ce2e9a046514028ab5f12e3e58832fd
Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus
Autor:
Illingworth, Sam, Di, Ying, Bauzon, Maxine, Lei, Janet, Duffy, Margaret R., Alvis, Simon, Champion, Brian, Lieber, André, Hermiston, Terry, Seymour, Len W., Beadle, John, Fisher, Kerry
Publikováno v:
In Molecular Therapy - Oncolytics 16 June 2017 5:62-74
Autor:
Chia, Suet-Lin, Lei, Janet, Ferguson, David J.P., Dyer, Arthur, Fisher, Kerry D., Seymour, Leonard W.
Publikováno v:
In Virology May 2017 505:162-171
Autor:
Dyer, Arthur, Di, Ying, Calderon, Hugo, Illingworth, Sam, Kueberuwa, Gray, Tedcastle, Alison, Jakeman, Phil, Chia, Suet Lin, Brown, Alice, Silva, Michael A., Barlow, David, Beadle, John, Hermiston, Terry, Ferguson, David J.P., Champion, Brian, Fisher, Kerry D., Seymour, Leonard W.
Publikováno v:
In Molecular Therapy - Oncolytics 17 March 2017 4:18-30